Navigation Links
New Therapy Found to Prevent Heart Failure
Date:6/23/2009

ROCHESTER, N.Y., June 23 /PRNewswire-USNewswire/ -- A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).

MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) is a clinical trial that enrolled more than 1,800 patients in the United States, Canada and Europe and followed the patients for up to 41/2 years. The results of the trial were released today by the University of Rochester Medical Center and Boston Scientific, the study's sponsor. The MADIT-CRT Executive Committee stopped the trial on June 22, 2009, when the trial achieved its primary end point - significant reduction in heart failure or death with CRT-D versus ICD-only. Cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, led the MADIT-CRT trial.

A prior study (MADIT-II) led by Moss and associates in 2002 showed the ICD was effective in reducing mortality. The current MADIT-CRT study sought to determine if CRT-D could reduce the risk of mortality and heart failure, which affects 5.7 million Americans, and the results were very positive.

Patients with heart disease have a risk of arrhythmias and heart failure. The new generation of cardiac resynchronization therapy defibrillators (CRT-Ds) was designed to stop dangerous, life-threatening heart rhythms and improve the heart's contraction, thereby enabling the device to improve survival and prevent heart failure.

CRT-Ds are approved for use in patients with severe heart failure (New York Heart Association class III/IV), whe
'/>"/>

SOURCE University of Rochester Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... funding commitment from a prominent international research and ... focus on promoting innovative research-based initiatives, including those ... nasal spray for the delivery of naloxone that ...
(Date:7/30/2014)... 2014  Hospira, Inc. (NYSE: HSP ... and infusion technologies, today reported results for the ... for the quarter were $1.1 billion and adjusted* ... exclude specified items as described later in this ... U.S. Generally Accepted Accounting Principles (GAAP) basis, second-quarter ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... studies show Treximet provided significantly more patients ... compared to sumatriptan 85 mg, LONDON, April 15 ... POZN ) announced today that the FDA has,approved Treximet ... in adults. Treximet is the first and only migraine product,designed ...
... Three new,Mayo Clinic studies find that REM (rapid eye ... scores in attention and,executive functioning, as well as symptoms ... American Academy of Neurology Annual,Meeting in Chicago on April ... (RBD) appear to act out,their dreams, which often are ...
Cached Medicine Technology:Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 2Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 3Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 4Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 5Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 6Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 7Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders 2
(Date:7/30/2014)... new network of 25 regional stroke centers and satellite ... is working to change the way stroke research ... the last two decades, stroke remains a major public ... for 795,000 Americans. The numbers are expected to rise ... To accelerate the pace of progress, NIH StrokeNet brings ...
(Date:7/30/2014)... Over 630 doctors worldwide are now certified ... minimally invasive treatment for gum recession. Santa Barbara, CA ... peers to be the “father of microsurgery” in periodontics ... Pinhole Surgical Technique® training course at the Chao Pinhole ... of the American Academy of Periodontics (AAP) 2010 Master ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s ... p.m. to 7 p.m. Wednesday, August 6 at the ... MI 48152). The event will feature Detroit Red Wings ... snacks and local public safety officials. Kohl’s will present ... Michigan Foundation. , The gift supports Kohl’s Injury ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... China Chitosan Industry” is a professional and ... market. The report provides basic Chitosan information, ... chain structure as well as industry overview. ... China’s domestic market as well as global ...
(Date:7/30/2014)... By Amy Norton ... -- Spending time in a garden might help soothe the ... suggests. Looking at 17 past studies, British researchers found ... garden can help soothe some dementia patients, anxiety. The ... patients are a tough subject to study -- and the ...
Breaking Medicine News(10 mins):Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3
... health care recruiting and staffing. Individuals have the choice of starting ... with an established Health Career Agents office. , ... ... now has three ways for qualified individuals to get involved in ...
... Corporation (NYSE Alternext US: FIT), a leading provider of ... that Gregg Lehman, Ph.D., president and chief executive officer ... the B. Riley & Co., LLC,s 10th Annual Las ... 11:00 a.m. PT. The conference will be held at ...
... Inc. (NYSE Alternext: ULU) today announced the ... as Chairman of the Company,s Scientific Advisory Board.Currently, Dr. ... for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. ... He also serves as the President and Chief Operating ...
... March 13 InterMune, Inc. (Nasdaq: ITMN ... Executive Officer and President of InterMune, will present at ... in Boston on March 17, 2009 at 3:10 p.m. ... investors and other interested parties may log on to ...
... MedQuist Inc. (Nasdaq: MEDQ ), a ... announce that it has resolved the investigation by the ... billing practices. Pursuant to the settlement, the Company ... litigation by the SEC, including an injunction against the ...
... U.S., expert says, , , FRIDAY, March 13 (HealthDay News) ... kidney disease, whether young or old, respond equally well ... passageways between veins and arteries to help in the ... fistulas the "gold standard of access for kidney dialysis ...
Cached Medicine News:Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3Health News:ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board 2Health News:MedQuist Announces Resolution of SEC Investigation 2Health News:Dialysis Via Fistulas May Help Young or Old 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... REA kit measures the biologically active form ... B6 is a valuable prognostic marker for ... low plasma vitamin B6 level and Coronary ... transamination reactions of homocysteine to cystathionine and ...
... for use with 4, 8, or 12 channel ... of nearly all of the solution. Corners have ... of natural virgin polystyrene containing no regrinds. Sterile ... irradiation. Dimensions: 78 mm W x 152 mm ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: